セロトニン受容体作用物質としてのN-置換ピペリジン誘導体

Japanese Patent JP2005533813

A

Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.

Anderson, Carl-Magnus
Shri Engel, Natalie
Fesic, Alma
Hansen, Eva, Louise
Paulus, Yang

JP2004516166A

November 10, 2005

June 20, 2003

Click for automatic bibliography generation  

Acadia Pharmaceuticals, Inc.

A61K31/4525; A61K31/453; A61K31/454; A61K31/4545; A61K31/517; A61K31/5377; A61P7/02; A61P9/00; A61P9/10; A61P9/12; A61P15/08; A61P15/10; A61P25/00; A61P25/02; A61P25/14; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/28; A61P25/32; A61P25/34; A61P25/36; A61P43/00; C07D211/58; C07D211/62; C07D401/06; C07D405/04; C07D405/06; C07D405/12; C07D405/14; C07D411/06; C07D413/06; C07D417/06; C07D521/00; (IPC1-7): C07D211/58; A61K31/4525; A61K31/453; A61K31/454; A61K31/4545; A61K31/517; A61K31/5377; A61P7/02; A61P9/00; A61P9/10; A61P9/12; A61P15/08; A61P15/10; A61P25/00; A61P25/02; A61P25/14; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/28; A61P25/32; A61P25/34; A61P25/36; A61P43/00; C07D401/06; C07D405/06; C07D405/12; C07D405/14; C07D413/06; C07D417/06

JP2003516965A	2003-05-20
JP2005533757A	2005-11-10

WO2001066521A1	2001-09-13
US6399619B1	2002-06-04

Takao Suzuki
Koichi Kajisaki
Yuzo Ozaki
Toshihiko Taniguchi

Previous Patent: 一酸化窒素、ヘムオキシゲナーゼ−１、およびヘム分解生成物の薬学的使�...

Next Patent: 新規ベンズイミダゾール−２−オン誘導体及びその使用方法